Perspectives on the future of psychiatry: treatment and training

Prevention, prediction of outcome and precision in therapy emerged as themes at the EPA 2021 symposium on how Psychiatry might most fruitfully develop. But sometimes you have to look back to look forwards: past success can guide our future direction as we move into uncharted territory. This is certainly the case with effective training.

Increased national and global recognition of the importance of mental health, a refinement and reduction in the adverse events of treatment, an enormously promising increase in our knowledge about the brain and greater respect for the human rights of people with mental illness – these are among the achievements making Norman Sartorius (Geneva, Switzerland) optimistic about the future of psychiatry.

Among the challenges he identifies is demographic change: a rapidly aging world population will greatly increase the physical comorbidities faced by people with mental health problems, and threaten to amplify their already large excess mortality.

In an aging population, comorbid physical ill-health is a growing challenge

Changes in family structure and functioning will reduce our capacity for care outside institutions and formal services, he predicted, while rapid urbanization brings social dislocation. And he lamented the commodification of medicine that may result in a culture in which we know the price of everything and the value of nothing, including the wellbeing of more vulnerable people in our communities.


Prevention and treatment both critical

If these challenges are to be met, primary prevention of mental illness will have to assume a far more important role, he suggested. 

Peter Falkai (Munich, Germany) took up the theme of treatment, with a view of the future in which genotyping will combine with phenotypic profiling to enable more accurate prediction of outcomes and personalization of therapy. And treatment will increasingly be based on a more developed understanding of disease mechanisms.

Genotyping will combine with phenotyping to more accurately predict outcomes and personalize therapy

Both speakers described the need for training to adapt to changing circumstances, and Peter Falkai emphasized the value of the clinician scientist – someone with time and training in both aspects of psychiatry and the ability to use clinical insights to inform meaningful research.


Back to the future

Andrea Fiorillo (Naples, Italy) looked back at successful programs, in which the EPA has had a major role, to nurture the development of early-career psychiatrists. Key elements include leadership and mentoring, networking and the cross-fertilization of ideas made possible through membership of professional societies.

We’ll need all the creativity we showed with the pandemic to meet unexpected future challenges

The future success of training – which will need us to promote recruitment into the specialty - requires continuity along these lines, he suggested. 

In terms of treatment strategy, he suggested relevant themes will be the rediscovering of psychopathology, early intervention, the integration of treatments, adapting to changing mental health targets, and – given the conjunction of physical and psychological comorbidity -- being physicians first and psychiatrists second.


EPA: European Psychiatric Association

BE-NOTPR-0061, approval date 08/2021

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.


During the symposium, speakers only expressed their opinion and personal experience. No actual data presented during the symposium.

You are leaving Progress in Mind
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intended for health care professionals.
All the information included in the Website is related to diseases, investigations and existing or potential treatment options and, therefore, directed to health professionals . The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Register for access to Progress in Mind in your country